Zydus receives final approval from the USFDA for Triazolam Tablets

Ahmedabad, India, 30 December, 2022

Zydus Lifesciences Limited (formerly known as Cadila Healthcare Limited) has received final approval from the United States Food and Drug Administration (USFDA) to market Triazolam Tablets USP, 0.125 mg and 0.25 mg (USRLD: HALCION® tablets).

Triazolam tablets are used on a short-term basis to treat insomnia (difficulty falling asleep or staying asleep). It works by slowing activity in the brain to allow sleep. The drug will be manufactured at the group's formulation manufacturing facility at Moraiya, Ahmedabad, India.

Triazolam tablets had annual sales of USD 11.7 million in the United States according to IQVIA data (IQVIA MAT Sept. 2022).

The group now has 339 approvals and has so far filed over 431* ANDAs since the commencement of the filing process in FY 2003-04.

*(*as of 30th September 2022)*

***

PRESS RELEASE

For further information please contact :
The Corporate Communications Department

Zydus Lifesciences Limited
(formerly known as Cadila Healthcare Limited)
Regd. Office : 'Zydus Corporate Park',
Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar),
Nr. Vaishnodevi Circle, S. G. Highway, Ahmedabad 382
481, Gujarat, India. | Phone : +91-79-71800000,
+91-79-48040000 | website : www.zyduslife.com
CIN : L24230GJ1995PLC025878